US SB3822

Prohibits any person from simultaneously owning or controlling both a health insurance company or pharmacy benefit manager (PBM) and a medical provider or management services organization, requiring divestiture within 1 year of enactment

Prohibits any person from simultaneously owning a prescription drug or medical device wholesaler and a medical provider or management services organization, also requiring divestiture within 1 year

Imposes penalties of 10% of monthly profits held in escrow for entities that fail to meet divestiture milestones, with funds forfeited to an FTC-administered fund if deadlines are missed; appoints a divestiture trustee with authority to sell assets if compliance is not achieved

Establishes enforcement authority for the FTC, DOJ Antitrust Division, HHS Inspector General, and State attorneys general, plus creates a private right of action with treble damages and attorney's fees for individuals harmed by violations

Requires FTC and DOJ to review all divestitures for effects on competition and public interest, and grants authority to block future transactions that would recreate the prohibited conflicts of interest